直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 118571
著者
Kadota, Naoki National Hospital Organization Kochi Hospital
Hatakeyama, Nobuo National Hospital Organization Kochi Hospital
Hino, Hiroyuki National Hospital Organization Kochi Hospital
國重, 道大 National Hospital Organization Kochi Hospital
Kondo, Yoshihiro National Hospital Organization Kochi Hospital
Okano, Yoshio National Hospital Organization Kochi Hospital
Machida, Hisanori National Hospital Organization Kochi Hospital
Naruse, Keishi National Hospital Organization Kochi Hospital
先山, 正二 National Hospital Organization Kochi Hospital KAKEN研究者をさがす
Ogushi, Fumitaka National Hospital Organization Kochi Hospital
Takeuchi, Eiji National Hospital Organization Kochi Hospital
キーワード
complete response
immune checkpoint inhibitor
pembrolizumab
plasma cell
pulmonary large cell neuroendocrine carcinoma
資料タイプ
学術雑誌論文
抄録
Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare and aggressive tumor with a poor prognosis and standard therapy has not yet been established.
Case: A 65-year-old male with a cough for 2 months presented to our hospital. He was clinically diagnosed with non small cell lung cancer cT3N1M0 stage IIIA and underwent right pneumonectomy. The final diagnosis was pulmonary LCNEC pT3N1M0 stage IIIA. Multiple subcutaneous masses were detected 4 months after surgery, and biopsy revealed postoperative recurrence and metastasis. Chemotherapy with carboplatin plus etoposide was initiated. Subcutaneous masses increased and multiple new brain metastases developed after two cycles. Additional tests revealed that epidermal growth factor receptor and anaplastic lymphoma kinase were negative, and the programmed death ligand 1 (PD-L1) expression rate in tumor cells was 40% (22C3 clones). The primary cells infiltrating the tumor were CD3-positive T cells and CD138-positive plasma cells. Second-line treatment with pembrolizumab was started. The shrinkage of subcutaneous masses was observed after one cycle, and the tumor had completely disappeared after six cycles. Treatment was continued for approximately 2 years. This response has been maintained for 4 years and is still ongoing.
Conclusion: Pembrolizumab may be used as a treatment option for pulmonary LCNEC.
掲載誌名
Cancer Reports
ISSN
25738348
出版者
Wiley Periodicals
5
8
開始ページ
e1589
発行日
2021-11-24
権利情報
This is an open access article under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
医学系